Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2023 07:18 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on...
November 01, 2023 16:52 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
October 02, 2023 16:27 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
September 06, 2023 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

NEW YORK and SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
September 01, 2023 16:37 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
August 09, 2023 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

Azenosertib monotherapy achieved an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients who received intermittent dosing Identified azenosertib monotherapy RP2D,...
August 01, 2023 16:28 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
August 01, 2023 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer

NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
June 15, 2023 06:01 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock

NEW YORK and SAN DIEGO, June 15, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
June 06, 2023 06:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D...